Dacarbazine (DTIC) in malignant melanoma

1976 ◽  
Vol 14 (10) ◽  
pp. 39-40

Malignant melanoma usually starts in the skin. Its primary treatment is wide excision with grafting of the wound. Most surgeons believe that involved lymph nodes are best removed before giving radiotherapy, chemotherapy or immunotherapy. Since melanoma is relatively insensitive to radiation and established cytotoxic drugs, the outlook for patients with metastatic disease is very poor.

Author(s):  
Kevin B. Hoover

Chapter 50 discusses sarcoidosis, which is a systemic disease that often involves the musculoskeletal system. The radiographic changes seen in sarcoid of the phalanges are characteristic, however, involvement of bone and other tissues may be occult or nonspecific. Tissue sampling is often required for diagnosis, especially when sarcoid resembles metastatic disease. The organ systems most commonly involved in sarcoid are the lungs, lymph nodes, skin and eyes. Radiographs are the standard first study used to evaluate symptomatic hand or foot involvement. Uncommon, palpable soft tissue lesions are best evaluated by MRI. Systemic corticosteroids are the primary treatment of active sarcoidosis.


2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Asad Khan ◽  
Sejal Patel ◽  
Daniel J. Zaccarini ◽  
Mary McGrath

Malignant Melanoma (MM) is among the most dangerous malignancies with some of the least known survival rates. Melanoma most commonly metastasizes to regional lymph nodes, the lungs, and brain. Metastatic disease of the gallbladder (GB) is exceptionally rare making it difficult to diagnose. The fact that typically patients do not present until they are symptomatic—only after widespread metastatic disease has already occurred—is further complicating the diagnosis of MM of the GB. For this reason, MM of the GB is rarely discovered in living patients. In fact, review of the literature showed only 40 instances in which metastatic disease of the GB was reported in living patients. We describe the presentation and management of a patient who had metastatic disease of the GB. However, our case is unique because his malignancy was discovered incidentally while he was asymptomatic. He was successfully treated with an open cholecystectomy. We have presented this case in order to make the necessity of meticulous investigation of potential metastasis in patients with a known history of cutaneous melanoma clear.


2021 ◽  
Vol 8 (1) ◽  
pp. 124-128
Author(s):  
Yanuar Hendra Wijaya ◽  
Nanda Daniswara ◽  
Ardy Santosa ◽  
Mohamad Adi Soedarso ◽  
Eriawan Agung Nugroho ◽  
...  

Background: Malignant melanoma of the penis is very rare, accounting for approximately 1.4% of all primary penile carcinomas. With a small prevalence of penile melanoma, there is lack of data about quality of the therapy. The primary treatment of melanoma of the penile is surgical, although there is a lack of consensus regarding the extent of treatment that is indicated. Case Report: A 60-year-old Caucasian man came to Division of Urology, Department of Surgery, Dr. Kariadi General Hospital Semarang with chief complaint painless and fast growing lesions on his penile. His general condition was fine, and has a normal vital signs. On the physical examination of penile region, there were found lesions on the ventral of the glans and penile foreskin and covered with blood and pus, with bilateral inguinal lymph nodes and lung metastasis from Multi Slice Computed Tomography. We already performed partial penectomy and bilateral inguinal lymph nodes dissection with histopathological results a malignant melanoma Clark IV. The final stage of penile melanoma was pT2N1M1. We follow-up the patient until 1 year after procedure, and there wasn’t any recurrence. Conclusion: Malignant melanoma of the penis is rare. Penile melanoma is highly treatable with surgical excision in its early stages because of resistant to both chemotherapy and radiotherapy. Delay in diagnosed and surgical treatment can lead to an adverse prognosis. The anamnesis, physical examination, and imaging studies must be done appropriately to improve the survival.


2017 ◽  
Vol 42 ◽  
pp. 158-160
Author(s):  
Eralda Mema ◽  
Emma Cho ◽  
Richard Ha ◽  
Bret Taback

2018 ◽  
Vol 26 (7) ◽  
pp. 552-557 ◽  
Author(s):  
Lieven P Depypere ◽  
Johnny Moons ◽  
Toni E Lerut ◽  
Willy Coosemans ◽  
Hans Van Veer ◽  
...  

Background Despite integrated positron emission tomography and computed tomography screening before and after neoadjuvant treatment in patients with locally advanced esophageal cancer, unexpected metastatic disease is still found in some patients during surgery. Should then esophagectomy be aborted or is there a place for palliative resection? Methods Between 2002 and 2015, 681 patients with potentially resectable esophageal cancer were sheduled for neoadjuvant therapy and subsequent esophagectomy. In 552 patients, a potentially curative esophagectomy was performed. In 12 patients, unexpected disease was discovered during surgery but esophagectomy was performed with synchronous resection of metastases; 10 of them had oligometastatic disease (≤4 single-organ metastases). Esophagectomy was not performed in 117 patients (because of disease progression in 50); 14 were also single-organ oligometastatic. Data of 10 single-organ oligometastatic patients who underwent esophageal resection (group 1) were compared those of 10 non-resected but treated counterparts (group 2) and with 228 patients who underwent potentially curative esophagectomy with persistent pathological lymph nodes (group 3). Results Five oligometastatic esophagectomy patients had lung metastases: 1 peritoneal, 2 adrenal, 1 pleural, and 1 pancreatic. Two oligometastatic non-resected patients had lung, 5 liver, and 3 brain metastases. Median overall survival was 21.4, 12.1, and 20.2 months in the respective groups (group 1 vs. group 2  p = 0.042; group 2 vs. group 3  p = 0.002; group 1 vs. group 3  p = 0.88). Conclusions Survival is longer in patients undergoing palliative esophagectomy with unexpected single-organ oligometastatic disease and comparable to survival in patients with persistent pathological lymph nodes. Palliative resection in these patients seems to be justified.


Author(s):  
Romualdo Silva Corrêa ◽  
Luciana Ayres de Oliveira Lima ◽  
Isa Maryana Araújo Bezerra de Macedo ◽  
Amália Cinhtia Meneses Rêgo ◽  
Irami Araújo-Filho

Colon cancer is a curable disease when restricted to the bowel and colectomy, the primary treatment. However, the presence and number of resected lymph nodes influence the therapeutic approach and prognosis of the patient. To evaluate the impact of the number of resected lymph nodes on the overall survival of patients treated for colon cancer at the League of Cancer Hospital - Natal - State of Rio Grande do Norte (RN) - Northeast Brazil. A retrospective observational study of 80 patients with colon cancer from Dr. Luiz Antônio Hospital (Natal-RN / Brazil), considering the period 2007-2014. Data were collected through medical records review. Survival rates were calculated and compared using the non-parametric Kaplan-Meier and Wilcoxon tests, respectively. All patients underwent radical surgical treatment associated or not with chemotherapy and/or radiotherapy treatment. The median survival time for the group of patients who had 12 or more resected lymph nodes was 9.4 years, in contrast to the 3.3 years of those who had less than 12 lymph nodes. Conclusion: It was concluded that a total of 12 or more resected lymph nodes confirmed by histopathology is associated with increased long-term survival in patients with colon cancer undergoing radical colectomy with or without chemotherapy and radiotherapy.


1997 ◽  
Vol 7 (Supplement 1) ◽  
pp. S84 ◽  
Author(s):  
A Blum ◽  
W Stroebel ◽  
H Breuninger ◽  
F Meier ◽  
B Schlagenhauff ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document